(Q38064483)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205468%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

review article

1 reference

title

Resiquimod, a topical drug for viral skin lesions and skin cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205468%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205468%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

4

Eggert Stockfleth

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205468%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

author name string

Thomas Meyer

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205468%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Christian Surber

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205468%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

language of work or name

English

0 references

publication date

4 December 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205468%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Investigational Drugs

19 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205468%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205468%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

page(s)

149-159

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205468%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205468%20AND%20SRC:MED&resulttype=core&format=json

Toll-like receptors: critical proteins linking innate and acquired immunity

19 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Antiviral applications of Toll-like receptor agonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Immunomodulating and antiviral activities of the imidazoquinoline S-28463.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Distinct TLR adjuvants differentially stimulate systemic and local innate immune responses in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Treatment of primary herpes simplex virus infection in guinea pigs by imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Effect of resiquimod 0.01% gel on lesion healing and viral shedding when applied to genital herpes lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Resiquimod and other immune response modifiers as vaccine adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Prevalence of solar damage and actinic keratosis in a Merseyside population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

High incidence and regression rates of solar keratoses in a queensland community.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Epidemiology of actinic keratoses and squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Malignant transformation of solar keratoses to squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Non-melanoma skin cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Skin cancer of the head and neck with clinical perineural invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Metastatic basal cell carcinoma: report of two cases and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Guidelines for the management of basal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Pharmacotherapy of actinic keratosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Emerging drugs for actinic keratosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: A prospective, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Herpes simplex virus and human papillomavirus genital infections: new and investigational therapeutic options

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Testing of herpes simplex virus for resistance to antiviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

The use of sinecatechins (polyphenon E) ointment for treatment of external genital warts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Green tea catechins for treatment of external genital warts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Various members of the Toll-like receptor family contribute to the innate immune response of human epidermal keratinocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Transcriptional networks in plasmacytoid dendritic cells stimulated with synthetic TLR 7 agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

The immune response modifier resiquimod mimics CD40-induced B cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Direct stimulation of human T cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN-gamma production by memory CD4+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

The novel synthetic immune response modifier R-848 (Resiquimod) shifts human allergen-specific CD4+ TH2 lymphocytes into IFN-gamma-producing cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Induction of apoptosis by Toll-like receptor-7 agonist in tissue cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Autocrine TNF is critical for the survival of human dendritic cells by regulating BAK, BCL-2, and FLIPL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

TRAIL(+) human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod- and IFN-α-mediated antitumor reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Therapy with TLR7 agonists induces lymphopenia: correlating pharmacology to mechanism in a mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

A phase II dose-ranging study of topical resiquimod to treat actinic keratosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Two-year interim results from a 5-year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: a long-term follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

A comparison of the skin permeation of three topical 0.5% fluorouracil formulations with that of a 5% formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Imiquimod: an immune response modifier in the treatment of precancerous skin lesions and skin cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Herpes simplex virus-2 in the genital mucosa: insights into the mucosal host response and vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Treatment of intravaginal HSV-2 infection in mice: a comparison of CpG oligodeoxynucleotides and resiquimod (R-848).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

The role of toll-like receptor ligands/agonists in protection against genital HSV-2 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Cutting edge: activation of murine TLR8 by a combination of imidazoquinoline immune response modifiers and polyT oligodeoxynucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

CpG DNA stimulates autoreactive immature B cells in the bone marrow

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Long-term follow-up of photodynamic therapy with a self-adhesive 5-aminolaevulinic acid patch: 12 months data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236

Ingenol mebutate gel for actinic keratosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.749236